Last reviewed · How we verify
NXP800
At a glance
| Generic name | NXP800 |
|---|---|
| Sponsor | Nuvectis Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma (PHASE1)
- A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NXP800 CI brief — competitive landscape report
- NXP800 updates RSS · CI watch RSS
- Nuvectis Pharma, Inc. portfolio CI